Abstract
BackgroundPrevious studies have shown that fibrinogen-to-albumin ratio (FAR) is a novel prognostic immune biomarker in various diseases. In this study, we investigated the role of FAR in the prognosis of patients with stage IB-IIA cervical cancer (CC).MethodsA total of 278 eligible participants with newly diagnosed CC (stage IB-IIA) who had undergone radical hysterectomy followed by adjuvant chemotherapy were enrolled in this study. Demographics, clinicopathological variables, and laboratory tests were obtained from the medical records. Risk factors for overall survival (OS) and recurrence-free survival (RFS) were evaluated by univariate and multivariate Cox proportional regression analyses. The association between OS, RFS, and FAR was assessed by the Kaplan–Meier method using log-rank test.ResultsFAR was associated with age, International Federation of Gynecology and Obstetrics (FIGO) stage, depth of the invasion, and C-reactive protein (CRP) level (P < 0.05). Preoperative FAR was an effective predictor for OS in CC patients with a cut-off value of 7.75 and an area under the curve (AUC) of 0.707 (P < 0.001). The univariate and multivariate Cox analyses indicated that FIGO stage and FAR were two independent risk factors for both OS and RFS (P < 0.05). Kaplan–Meier analysis confirmed that patients with high FAR levels showed significantly lower RFS (P = 0.004) and OS (P = 0.003) than those with low FAR levels.ConclusionsThis study indicated that elevated preoperative FAR might be a novel prognostic factor for CC patients with stage IB-IIA.
Highlights
Previous studies have shown that fibrinogen-to-albumin ratio (FAR) is a novel prognostic immune biomarker in various diseases
While the incidence and mortality of invasive CC have markedly decreased over time, it still ranks as the third most common cancer in women, with approximately 250,000 patients dying from CC each year globally [2]
The inclusion criteria were as follows: (a) newly diagnosed CC patients with the Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA; (b) with clinicopathological and laboratory data including Alb and Fig; (c) who had undergone radical hysterectomy followed by adjuvant chemotherapy; (d) with five-year follow-up data
Summary
Previous studies have shown that fibrinogen-to-albumin ratio (FAR) is a novel prognostic immune biomarker in various diseases. We investigated the role of FAR in the prognosis of patients with stage IB-IIA cervical cancer (CC). Alb has been reported to be a well-established prognostic factor in patients with various diseases, including oral cavity cancer [10], metastatic pathological femur fractures [11], and amyotrophic lateral sclerosis [12]. The prognostic role of Fib has been reported in various studies, such as spontaneous intracerebral haemorrhage [13] and surgically resected non-small-cell lung cancer [14]. The Fib-to-Alb ratio (FAR), which considers both inflammatory biomarkers, is a novel prognostic immune biomarker in various diseases, e.g. gallbladder cancer [15], breast cancer [16], and ST-segment elevation myocardial infarction [17]. Whether FAR could be a prognostic factor for CC has never been examined, which is the main aim of this study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
